<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03179800</url>
  </required_header>
  <id_info>
    <org_study_id>CRD0447</org_study_id>
    <nct_id>NCT03179800</nct_id>
  </id_info>
  <brief_title>CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™</brief_title>
  <acronym>CALM-2</acronym>
  <official_title>CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vascular Dynamics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vascular Dynamics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and effectiveness of the MobiusHD
      System in a prospective, randomized, double-blind, sham-controlled multi-center pivotal
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the safety and effectiveness of the MobiusHD
      System in a prospective, randomized, double-blind, sham-controlled multi-center pivotal
      study. Patients with resistant hypertension who remain uncontrolled despite pharmacologic
      treatment with maximum tolerated, guideline-directed anti-hypertensive pharmacologic therapy
      will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2017</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Effectiveness Endpoint - Change in mean 24-hr sABP from baseline to 180-day</measure>
    <time_frame>180-day</time_frame>
    <description>The primary effectiveness endpoint is change in mean 24-hr ambulatory systolic blood pressure (24hr sABP) from baseline to the 180-day visit.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Safety Assessments - Composite measured at 90-day</measure>
    <time_frame>90-day</time_frame>
    <description>Composite measure of death, MI, stroke, device embolization, carotid occlusion, new ipsilateral carotid stenosis requiring surgical or percutaneous intervention, or Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding events as adjudicated by CEC from randomization through the 90-day visit. All adverse events.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hypertension</condition>
  <condition>Resistant Hypertension</condition>
  <arm_group>
    <arm_group_label>MobiusHD Implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MobiusHD Implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Implantation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham Implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MobiusHD</intervention_name>
    <description>The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.</description>
    <arm_group_label>MobiusHD Implantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Implantation</intervention_name>
    <description>Sham Implantation</description>
    <arm_group_label>Sham Implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mean 24 hour ambulatory systolic blood pressure ≥145 mmHg and ≤200 mmHg and stable for
             at least 8 weeks on a maximally tolerated guideline directed, (JNC8) or their
             equivalent when those listed are not available dosing regimen consisting of up to 5
             antihypertensive medications, with a minimum required dosing regimen of an &quot;A+C+D&quot;
             antihypertensive medication regimen, where &quot;A&quot; is an angiotensin-converting enzyme
             Inhibitor or an angiotensin receptor blocker, &quot;C&quot; is a calcium channel blocker, and
             &quot;D&quot; is a diuretic.

        Exclusion Criteria:

          -  Inadequacy of the carotid anatomy for treatment with the MobiusHD based on carotid
             angiography.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryan Williams, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregg Stone, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiovascular Research and Education Columbia University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suji Shetty, MD</last_name>
    <phone>650-963-9029</phone>
    <email>sshetty@vasculardynamics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Carl &amp; Edyth Lindner Center for Research &amp; Education at The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxanne Robertson, RN</last_name>
      <phone>513-585-1777</phone>
      <email>Roxanne.robertson@thechristhospital.com</email>
    </contact>
    <contact_backup>
      <last_name>Darlene Rock, RN, BSN, MBA</last_name>
      <phone>513-585-1766</phone>
      <email>Darlene.rock@thechristhospital.com</email>
    </contact_backup>
    <investigator>
      <last_name>John J Szawaluk, MD, FACC, FAHA, FSCTT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vasculardynamics.com/</url>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2017</study_first_submitted>
  <study_first_submitted_qc>June 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Resistant Hypertension</keyword>
  <keyword>Baroreceptor</keyword>
  <keyword>BAT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

